Federated Hermes, Inc. Lipocine Inc. Transaction History

Federated Hermes, Inc.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 13, 2020	SELL	$0.42 - $1.26 $30 - $90	-72 Closed	0 $0
Q1 2020 May 13, 2020	SELL	$0.32 - $0.77 $6 - $16	-21 Reduced 22.58%	72 $1,000
Q4 2019 Feb 14, 2020	SELL	$0.32 - $3.15 $12 - $126	-40 Reduced 30.08%	93 $1,000
Q3 2019 Nov 14, 2019	SELL	$1.79 - $3.33 $311 - $579	-174 Reduced 56.68%	133 $1,000
Q2 2019 Aug 14, 2019	SELL	$1.43 - $2.32 $466 - $756	-326 Reduced 51.5%	307 $1,000
Q1 2019 May 10, 2019	SELL	$1.46 - $2.33 $1,078 - $1,721	-739 Reduced 53.86%	633 $1,000
Q4 2018 Feb 13, 2019	SELL	$1.07 - $1.63 $1,944 - $2,961	-1,817 Reduced 56.98%	1,372 $1,000
Q3 2018 Nov 13, 2018	SELL	$1.31 - $1.63 $2,775 - $3,453	-2,119 Reduced 39.92%	3,189 $4,000
Q2 2018 Aug 10, 2018	SELL	$1.06 - $1.78 $5,198 - $8,729	-4,904 Reduced 48.02%	5,308 $7,000
Q1 2018 May 09, 2018	SELL	$1.18 - $3.46 $87,609 - $256,887	-74,245 Reduced 87.91%	10,212 $16,000
Q4 2017 Feb 14, 2018	SELL	$3.36 - $4.35 $4,021 - $5,206	-1,197 Reduced 1.4%	84,457 $0
Q3 2017 Nov 13, 2017	BUY	$3.67 - $4.19 $314,350 - $358,890	85,654	85,654 $340,000

Ticker LPCN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 88,510,800
Market Cap $387M
Description
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone rep...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.